Dachaigh › Gnìomhan › Natural Sciences Managers › San Francisco, CA
Natural Sciences Managers ann an San Francisco, CA: Tuarastalan H-1B
27 iarrtasan cumhaichean-obrach airson an dreuchd seo le làrach-obrach ann an San Francisco, CA. Tuarastal bunasach meadhanach $218,500; leth meadhanach $109,366–$250,000.
A rèir ìre tuarastail
| Ìre tuarastail | Tuarastal meadhanach |
|---|---|
| Ìre I (innte) | $131,248 |
| Ìre II (càileachail) | $109,366 |
| Ìre III (eòlach) | $248,082 |
| Ìre IV (gu lèir comasach) | $289,000 |
Suidhichidh Roinn an Obrach ceithir ìrean tuarastail làithreach airson gach dreuchd agus sgìre, bho Ìre I (inntrigeadh) gu Ìre IV (gu tur comasach). Taghaidh an neach-fastaidh an ìre a fhreagras ri riatanasan na h-obrach.
Luchd-fastaidh
| Neach-obrach | LCAs | Tuarastal meadhanach |
|---|---|---|
| University of California, San Francisco | 4 | $95,296 |
| The J. David Gladstone Institutes | 3 | $109,366 |
| Parker Institute for Cancer Immunotherapy | 3 | $250,000 |
| Syneos Health US, Inc. | 2 | $256,350 |
| Nuvation Bio Inc | 2 | $370,000 |
| Astellas Pharma Global Development, Inc. | 1 | $131,914 |
| Alliance for Sustainable Energy, LLC | 1 | $76,000 |
| Vector Oncology, LLC | 1 | $174,158 |
| FibroGen, Inc. | 1 | $130,582 |
| The Smith-Kettlewell Eye Research Institute | 1 | $72,696 |
| PPD Development, L.P. | 1 | $233,210 |
| 89Bio, Inc. | 1 | $273,250 |
| Olema Pharmaceuticals, Inc. | 1 | $218,500 |
| Redwood Materials, Inc. | 1 | $215,000 |
| Truveta, Inc. | 1 | $249,000 |
| Aligos Therapeutics, Inc. | 1 | $248,082 |
| Lila Sciences, Inc. | 1 | $248,082 |
| Genentech, Inc. | 1 | $291,304 |
Tiotalan dreuchd
- Research Director3
- Senior Clinical Research Coordinator3
- Vice President, Clinical Operations2
- Assistant Investigator1
- Senior Manager, CPED Oncology [20357.321.8]1
- Project Manager II - Research1
- Scientific Program Leader I1
- Clinical Research Analyst 41
- Director, Outcomes Science and Services1
- Director, FSC Solution Design1
- Clinical Trial Manager1
- Director - Consulting1
- Research Coordinator1
- Medical Director1
- Senior Medical Director of Drug Safety and Pharmacovigilance1
Luchd-taic H-1B ann an San Francisco, CA →
Is e na tuarastalan an ìre as ìsle den tuarastal a chaidh a thabhann air gach iarrtas, air an tionndadh gu suim bhliadhnail; cleachdaidh na staitistigean iarrtasan làn-aimsire le teisteanas a-mhàin. Chan eil LCA na aontachadh bhìosa agus faodaidh aon LCA còmhdach a dhèanamh air iomadh dreuchd. Stòr: Roinn an Obrach na SA, Dàta Foillseachaidh OFLC LCA, bliadhnaichean ionmhais 2023–2026 (co-dhùnadh as ùire 30 Ògmh 2026).